- Home
- FENG vs ENLV Comparison
FENG vs ENLV Comparison
Compare FENG & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FENG
- ENLV
- Stock Information
- Founded
- FENG 1998
- ENLV 2005
- Country
- FENG China
- ENLV Israel
- Employees
- FENG N/A
- ENLV N/A
- Industry
- FENG Broadcasting
- ENLV Biotechnology: Pharmaceutical Preparations
- Sector
- FENG Industrials
- ENLV Health Care
- Exchange
- FENG Nasdaq
- ENLV Nasdaq
- Market Cap
- FENG 26.8M
- ENLV 25.5M
- IPO Year
- FENG 2011
- ENLV 1995
- Fundamental
- Price
- FENG $2.88
- ENLV $1.03
- Analyst Decision
- FENG
- ENLV Strong Buy
- Analyst Count
- FENG 0
- ENLV 2
- Target Price
- FENG N/A
- ENLV $10.00
- AVG Volume (30 Days)
- FENG 35.0K
- ENLV 180.9K
- Earning Date
- FENG 11-11-2025
- ENLV 08-29-2025
- Dividend Yield
- FENG N/A
- ENLV N/A
- EPS Growth
- FENG N/A
- ENLV N/A
- EPS
- FENG N/A
- ENLV N/A
- Revenue
- FENG $101,168,374.00
- ENLV N/A
- Revenue This Year
- FENG N/A
- ENLV N/A
- Revenue Next Year
- FENG N/A
- ENLV N/A
- P/E Ratio
- FENG N/A
- ENLV N/A
- Revenue Growth
- FENG 5.53
- ENLV N/A
- 52 Week Low
- FENG $1.28
- ENLV $0.81
- 52 Week High
- FENG $3.65
- ENLV $2.10
- Technical
- Relative Strength Index (RSI)
- FENG 58.67
- ENLV 40.19
- Support Level
- FENG $2.56
- ENLV $1.02
- Resistance Level
- FENG $3.65
- ENLV $1.08
- Average True Range (ATR)
- FENG 0.19
- ENLV 0.04
- MACD
- FENG 0.04
- ENLV 0.01
- Stochastic Oscillator
- FENG 44.28
- ENLV 33.33
About FENG Phoenix New Media Limited
Phoenix New Media Ltd is a media company providing premium content on an integrated platform across the internet, mobile and TV channels in China. The company organizes its operations into two main segments: Net advertising services and Paid services. It provides its content and services through three channels: ifeng.com channel, video channel, and mobile channel. The company also offers a wide range of paid services including mobile value-added services, games, and content sales. It generates the majority of its revenue from Net advertising services. Geographically, it derives revenue from China.
About ENLV Enlivex Therapeutics Ltd.
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.